Effectiveness and safety of first-line therapies, dual immunotherapy versus immunotherapy plus targeted therapy in advanced renal cell carcinoma: A systematic review and meta-analysis
{{output}}
IntroductionThe preferred first-line regimen in advanced renal cell carcinoma (aRCC) remains uncertain, because rapid evolution of immunotherapy-based combination regimens quickly outdates the existing evidence. Current strategies for synthesizing these data l... ...
